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Abstract. Several studies of deep brain stimulation (DBS) of the fornix or the nucleus basalis of Meynert have been recently
conducted in people with Alzheimer’s disease, with several recruiting participants <65 and thus have early-onset Alzheimer’s
disease (EOAD). Although EOAD accounts for less than 5.5% of AD cases, ethical considerations must still be made
when performing DBS trials including these participants since a portion of people with EOAD, especially those possessing
autosomal-dominant mutations, have an atypical and more aggressive disease progression. These considerations include
appropriate patient selection and signing of an informed consent for genetic testing; appropriate study design; potential
outcomes that people with EOAD could expect; and accurate interpretation and balanced discussion of trial results. Finally,
recommendations for future DBS for AD trials will be made to ensure that EOAD patients will not experience avoidable
harms should they be enrolled in these experimental studies.
Keywords: Clinical trials as topic, deep brain stimulation, early onset Alzheimer’s disease, ethical review, ethics, familial
Alzheimer’s disease, fornix (brain), nucleus basalis of Meynert
INTRODUCTION
There has been a recent surge in experimental tri-
als on deep brain stimulation (DBS) for Alzheimer’s
disease (AD) [1–5], with several studies recruiting
participants <65 [1, 3–5] and thus have early-onset
Alzheimer’s disease (EOAD). Although there have
already been previous discussions on the ethics of
DBS for neurodegenerative disorders [6–9], issues
arising from recruiting people with EOAD for DBS
∗Correspondence to: John Noel M. Vian˜a, MSc, University of
Tasmania, Private Bag 41, Hobart, Tasmania 7001, Australia. Tel.:
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trials remain unexamined and unexplored in the lit-
erature. To address this gap, we discuss potential
ethical issues focusing on selection criteria, genetic
testing and informed consent, study design, measured
outcomes, and result interpretation and portrayal to
protect people with EOAD participating in DBS for
AD trials.
EARLY-ONSET ALZHEIMER’S DISEASE
AND GENETIC PREDISPOSITION
Dementia affects an estimated 46.8 million peo-
ple worldwide [10], with AD as its leading cause
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Co
rre
ct
d P
roo
f
2 J.N.M. Vian˜a et al. / Ethics of DBS Trials in Patients with EOAD
[11]. People with AD dementia suffer from cognitive
or behavioral impairment in two or more domains,
which include memory, reasoning and executive
function, visuospatial abilities, language functions,
and personality, that significantly interferes with abil-
ity to function at work or at usual activities [12].
Although the majority of people with AD are ≥65
[13], 5.5% of those affected have an onset of demen-
tia before 65 [14] and thus are classified as having
EOAD. The 65-year-old cut-off point has no bio-
logical significance and is mainly an indicative of
social divide in terms of employment and retirement
age [15]. Nonetheless, people with EOAD usually
have a more rapid disease progression and have more
pronounced brain pathology compared to those who
develop AD symptoms after 65 [16]. In addition, they
have a much shorter survival time; much more preva-
lent language disturbance [17]; exhibit other atypical
symptoms such as visual agnosia, apraxia, dyscal-
culia, and executive dysfunction [18]; have a higher
prevalence of additional non-cognitive neurological
symptoms [19]; and exhibit more severe temporopari-
etal junction atrophy [20].
At least 62% of patients with EOAD have a history
of AD in the family [21], implying potential genetic
underpinnings. Currently, three genes have been fully
established to cause highly penetrant and autoso-
mal dominant AD: amyloid precursor protein (APP)
and presenilin 1 and 2 (PSEN1 and PSEN2). PSEN1
makes up 30 to 70% of familial EOAD (EOFAD); fol-
lowed by APP that accounts for 10–15% of EOFAD
cases; and lastly, by PSEN2 that accounts for less than
5% of all EOFAD [22, 23]. Mutations in APP causes
its aberrant processing and increased A42 secretion,
whereas mutations in PSEN1 or PSEN2 lead to aber-
rant cleavage of APP by -secretase, resulting in an
overproduction of A42 [16]. Overall, this leads to
the biological cascade causing the observed cogni-
tive defects in AD. The age of AD onset in PSEN1
mutation carriers is between 30 and 50 years old, 40 to
70 years in PSEN2, and 45 to 60 years in APP muta-
tion carriers. Atypical presentations such as language
impairment and behavioral symptoms such as delu-
sion, hallucinations, and apathy have been observed
in those with PSEN1 or PSEN2 mutations [22]. Cer-
tain APP mutations have also been linked to cases
of congophilic angiopathy [23], which can lead to
leukoencephalopathy, stroke-like episodes, hemor-
rhage, and cortical calcification [19].
Even though APP, PSEN1, and PSEN2 muta-
tions are the only ones definitively proven to cause
autosomal-dominant EOAD, the presence of an
APOE 4 allele has also been associated as a risk fac-
tor for typical AD and potentially reduces its age of
onset by roughly 10 years. It is not a necessary com-
ponent though since patients who typically exhibit
an atypical and early-onset AD course, exhibiting
focal cortical, non-memory impairments, and a more
aggressive progression, can develop AD even in the
absence of an APOE 4 allele [18]. Nonetheless,
patients who have APP, PSEN1, or PSEN2 mutations
could also have a much earlier age of onset if they
possess an APOE 4 allele [23, 24].
Currently, people diagnosed with EOAD are given
the same treatment as those who have late-onset
Alzheimer’s disease (LOAD), given similarities in
pathogenesis and clinical features [19]. Only six
drugs are FDA-approved for the management of AD
symptoms; however, none of them stops disease pro-
gression [25], treats the underlying pathology, or
provides long-term benefit [26]. As such, several clin-
ical trials on different modes of treatment are being
undertaken to either provide additional long-lasting
relief from symptoms or treat the underlying AD neu-
ropathology. Among the treatment modalities being
investigated is DBS, a procedure wherein leads are
inserted into the brain region of interest to deliver
continuous electrical stimulation [27], with the hope
of ameliorating cognitive dysfunction. Currently,
DBS has regulatory approval for essential tremor,
Parkinson’s disease, dystonia, obsessive-compulsive
disorder, and epilepsy [28].
CLINICAL STUDIES ON DEEP BRAIN
STIMULATION FOR AD
The first experimental trial on DBS for AD was
performed in 1984 where the nucleus basalis of
Meynert (NBM) was stimulated. Although there was
no improvement in memory or cognition, preserved
cortical glucose metabolic activity in the left pari-
etal and left temporal lobes and partial arrest of
deterioration in the left frontal area were observed
[29]. The next clinical trial was performed 26 years
later [1], and was driven by a serendipitous discov-
ery in 2008 when DBS of the fornix to treat obesity
resulted to “deja vu-like” sensations during surgery
and improvements in episodic verbal and associative
memory after three weeks of stimulation [30]. The
2010 Phase I trial investigated DBS of the fornix in
six patients with early AD. Similar to the 2008 study,
two patients experienced autobiographical experi-
ential phenomena during surgery. In addition, after
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12 months of continuous DBS, some patients were
reported to have improved memory and reduced cog-
nitive decline, reversed glucose metabolism [1], and
increased hippocampal volume [31]. Given that the
Phase I trial was considered to have proven the
safety of DBS of the fornix and showed metabolic
changes associated with it, a Phase II randomized,
double-blind, placebo-controlled, delayed-start trial
is currently being conducted in 42 subjects with mild,
probable AD. In this trial, half of the subjects will
not receive any stimulation while the other half will
receive continuous DBS stimulation for 12 months;
after which, all participants will receive stimulation
for 12 months [32]. Results of the first year of this
trial have already been published and indicate no sig-
nificant difference in cognitive scores between those
who received and those who did not receive stimula-
tion. However, stratifying participants based on age
showed that those who are <65 actually significantly
worsened after DBS for one year, whereas those
≥65 had a slight improvement in cognitive function.
In terms of safety, there were 145 and 117 non-
serious adverse events in patients that received and
did not receive stimulation, respectively. In addition,
nine serious adverse events for each participant sub-
group were reported. Serious adverse events include
those that lead to prolonged hospital stay, new hospi-
tal admission, disability, or death, such as infection,
lead repositioning, post-op nausea, depression, suici-
dal ideation, and worsening confusion. Non-serious
adverse events are predominantly general medical in
nature, followed by psychiatric events. Taking into
account the nature and extent of reported adverse
events, an independent data and safety monitoring
board concluded that the observed safety profile was
as expected with deep brain stimulation [3].
Aside from the aforementioned Phase I [1] and
Phase II trials [3] of fornix DBS in North Amer-
ica, several other case studies and trials of DBS for
patients with AD have been reported. A team in
France performed fornix DBS in a patient with mild
cognitive decline. After 12 months of stimulation, the
patient’s cognitive performance reportedly stabilized,
and the patient also had increased mesial temporal
lobe metabolism [2]. Aside from the study done in
1984 [29], another trial of DBS of the NBM was
also performed by Kuhn et al. [4] where six patients
with mild to moderate AD received bilateral DBS.
Their study consisted of an initial one-month ran-
domized sham-controlled stimulation phase, where
two weeks of stimulation was followed by two weeks
without stimulation or vice versa, and a succeeding
11-month phase of continued open stimulation on
all patients. During the first month, mean Mini-
Mental State Examination (MMSE) scores improved
after two-weeks of stimulation compared to the
score after two weeks without stimulation. After
almost a year of stimulation, cognitive assessments
revealed slower disease progression when compared
to patients undergoing medication. In addition, some
patients exhibited increased temporal and amygdalo-
hippocampal glucose metabolism after almost a year
of stimulation. In terms of safety, the surgical proce-
dures were well tolerated, and the patients had fast
recovery and did not have significant stimulation-
induced untoward effects [4]. Kuhn et al. [5] then fur-
ther extended their study and performed continuous
DBS of the NBM in two patients who have an average
age younger than the average of those in the Phase
I trial and who both have lower baseline ADAS-Cog
scores. One participant deteriorated after 26 months
based on ADAS-Cog and MMSE scores, whereas the
other participant had a stable ADAS-Cog and even
improved MMSE score after 28 months. Hardenacke
et al. [33] then collated the results of the Phase I trial
[4] and that of the two new patients [5] and suggested
that NBM-DBS performed at a younger age and at an
earlier disease stage may favorably impact cognitive
functions and disease progression.
ETHICAL CONSIDERATIONS ON DBS
STUDIES ON PEOPLE WITH EOAD
Majority of the trials [1, 2, 4, 32] performed or
currently ongoing recruited patients who are less
than 65 years old, and thus could potentially have
EOAD. Given that DBS is an invasive procedure that
could lead to a number of neurologic and psychiatric
unwanted side effects [34], it is important to consider
ethical issues that may arise when performing it to
different patient subgroups, especially to individuals
less than 65 who might have certain mutations that
could lead to a more aggressive disease course [16].
Considerations for patient selection
Four out of six reported studies [1, 2, 4, 32] posted
recruitment details on the clinicaltrials.gov database
and described them in their papers (Table 1). From
this information, it is evident that five out of six
DBS for AD studies recruited a total of 19 partici-
pants <65, all of which have at least mild cognitive
impairment. This indicates an overrepresentation of
EOAD in the study population (32.7%) given that
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Table 1
Criteria for patient recruitment in studies on DBS for AD and number of recruited participants who are less than 65
Study Region N<65 Age AD stage Cognitive score Biomarker Suicidality Informed consent
Turnbull et al. [29] NBM 0/1 No mention
Laxton et al. [1] fornix 5/6 40–80 Probable AD (1983
NINCDS-ADRDA)
CDR of 0.5–1,
MMSE of 18–28
– – Patient or surrogate
Fontaine et al. [2] fornix 0/1 50–70 AD DSM IV Episodic memory
impairment from
FCSRT/ Grober and
Buschke test;
MMSE of 20 to 24
MRI and/or CSF
and/or PET
proposed to patient
– Patients
Kuhn et al. [4] NBM 1/6 57–80 Mild to moderate AD – DSMIV,
ICD10, NINCDS-ADRDA
MMSE >18, <26 CSF of tau and A42 Suicidal tendency Patients and at least 2
family members
Kuhn et al. [5] NBM 1/2 No mention
Holroyd et al. [32];
Lozano et al. [3]
fornix 12/42 45–85 Probable AD (2012 NIA-AA) CDR of 0.5 to 1;
ADAS-Cog 11 of
12–24, score ≥4 on
Item 1: immediate
recall
– Suicide past 2 years;
C-SSRS
Subject, caregiver,
and surrogate
NBM, nucleus basalis of Meynert; NINDS-ADRDA, National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer’s Disease and Related Disorders
Association (ADRDA); DSM, Diagnostic and Statistical Manual of Mental Disorders; ICD10, World Health Organization International Statistical Classification of Diseases and Related Health
Problems; NIA-AA, National Institute on Aging-Alzheimer’s Association; CDR, Clinical Dementia Rating scale; MMSE, Mini-Mental State Exam; FCSRT, Free and Cued Selective Reminding
Test; ADAS-Cog 11, Alzheimer’s Disease Assessment Scale – cognitive component; C-SSRS, Columbia Suicide Severity Rating Scale; CSF, cerebrospinal fluid.
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only around 5.5% of people with AD have an early
disease onset [14]. Such overrepresentation of EOAD
patients might not have been deliberately made by
the authors and could have just been a result of better
success in recruiting and enrolling younger patients
due to their greater capacity to tolerate surgery [35]
and provide consent [36]. Furthermore, these studies
did not mention performing any family background
checks or genetic tests for APP, PSEN1, and PSEN2,
which makes it possible that a participant enrolled
could also have familial (EOFAD) or autosomal-
dominant EOAD (AD-EOAD). If one considers that
the proportion of autosomal dominant EOAD patients
among all EOAD patients is 13% [21], then it seems
likely that at least two patients (13% of 18 = 2.34)
with AD-EOAD have already participated in these
trials. Interestingly, patient 3 in the Phase I trial
of Laxton et al. [1] was below 65, had an aggres-
sive disease course prior to surgery based on MMSE
scores, and had the worst outcome post-DBS based on
MMSE scores. As such, patient 3 might actually have
a form of EOFAD or AD-EOAD; however, this can-
not be ascertained given that no family background
checks or genetic tests were presented in the report.
Considering that people <65 are being recruited in
DBS for AD studies, we suggest considerations and
adjustments in certain inclusion and exclusion criteria
when patients with EOAD are potentially recruited
in studies, especially those who have autosomal-
dominant EOAD.
First, since certain AD-EOAD patients could
exhibit atypical behavioral symptoms and DBS could
have unwanted psychiatric effects [34], recruited
EOAD patients should not have any major psychi-
atric disorder, especially those that increase the risk
of suicide, such as depression, schizophrenia, and
substance use disorders [37, 38]. Participants with
a history of and/or who were experiencing suici-
dal ideations at the time of recruitment should be
excluded in trials considering that suicidality is a
potential adverse event of DBS [39–41]; patients with
AD have an increased risk of committing suicide [42];
and people with certain autosomal AD mutations
have a high risk of depression and disinhibition [43].
Of all the studies of DBS for AD, only two studies
[4, 32] specifically excluded patients who had previ-
ous suicide attempts or who have suicidal ideations.
Moreover, should appropriate consent be given to
employ genetic testing in patients with a family his-
tory of AD, careful counselling should be provided
to minimize the risks of increased suicidal ideation
from an untoward result. Proper tests and monitoring
should then be made to ensure that individuals with
positive results do not exhibit any suicidal tendencies
or ideations prior to commencing DBS surgery.
Second, potential adjustments in the required cog-
nitive profile and disease stage of recruited EOAD
patients should be made to account for its shorter
disease duration and more aggressive course, espe-
cially in participants who have autosomal-dominant
mutations [22]. In past and ongoing studies of DBS
for AD, some trials [1, 2, 32] only recruited patients
with mild AD, whereas Kuhn et al. [4] also included
those with moderate AD. In terms of cognitive profile,
two studies [1, 32] recruited patients with a Clinical
Dementia Rating (CDR) of up to 1, two studies [1, 4]
recruited patients with MMSE as low as 18, and one
study [32] recruited patients that have an ADAS-Cog
11 score as high as 26. The inclusion of patients with
CDR, MMSE, and ADS-Cog 11 scores that already
signify cognitive decline beyond the mild cognitive
impairment stage [44] and at the start of the dementia
phase warrants serious consideration when patients
with EOAD are included in a study, given EOAD’s
more aggressive disease course [16]. Considering the
initial results of Laxton et al. [1] and Hardenacke et al.
[33] showing that patients in an earlier disease stage
are more likely to benefit from DBS, there is a need to
modify the cognitive status cut-offs for participants
<65 participating in DBS for EOAD studies. EOAD
patients that have a CDR score >0.5, MMSE score
<23, and ADAS-Cog 11 score >18 [45], and possess
mutations predisposing them to more aggressive cog-
nitive deterioration [22, 23] should not be included in
DBS studies unless more evidence has been gathered
regarding the efficacy of DBS in later AD stages.
Although the use of most biomarker data as diag-
nostic tools has not yet been approved clinically,
hippocampal volume, tau, and A cerebrospinal fluid
levels, and brain activity [46] could also be used
in conjunction with cognitive tests to ensure that
enrolled EOAD patients are at an early disease stage.
Third, it is important to consider the effect of
excluding or only including certain patient subgroups
based on participants cognitive, genetic, and/or
biomarker profile on the study’s external and inter-
nal validity and also to determine whether it violates
the clinical responsibility to provide patients access to
certain treatments [47]. Excluding participants with
EOAD or including only EOAD participants might
increase a study’s internal validity due to increased
subject homogeneity; however, such could also con-
sequently diminish a study’s external validity [48,
49]. Although preliminary trials on drugs and certain
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interventions are often done on more homogeneous
populations as a result of relatively narrow selec-
tion criteria [50], participant recruitment for invasive
neurosurgical procedures such as DBS could be
extremely challenging, especially when highly strin-
gent selection criteria are employed [2]. As such,
recruiting an immensely homogeneous sample might
not be possible in the context of preliminary DBS
trials. Furthermore, trials including different popu-
lations for invasive procedures could provide better
knowledge of different subpopulations that could be
more responsive to treatments, provided that no sub-
population is significantly disadvantaged or harmed
by the intervention in accordance with the ethics
principle of Nonmaleficence [7, 51]. However, since
initial results from the Phase II fornix DBS trials sug-
gest that participants <65 could worsen from DBS
[3], excluding them from subsequent fornix DBS tri-
als, especially those with moderate AD, might be
warranted until subsequent in-depth analyses have
been made to ascertain if age is indeed the sole
causative factor associated with the observed decline
or if other variables such as genetic and cognitive
status actually better explain the variable effects of
treatment between different patient subgroups. This
further emphasizes the importance of obtaining addi-
tional information on genetic status and biomarker
information in participants so that those who are
either likely to benefit or are likely to be harmed by
DBS would be better and more precisely identified.
Given that DBS for AD has not been approved yet
by an established regulatory body (e.g., FDA) as a
standard of care and its application is still in the con-
text of clinical trials, denying access to it for certain
patient subgroups could not be considered as denial
of treatment.
Genetic vulnerability and informed consent
Since the corresponding clinical progression
resulting from certain AD-associated mutations has
already been recorded [23], making the correct
adjustments such as allowable time period to with-
hold treatment and frequency of monitoring for
patients with certain EOAD genetic subtypes would
be much better facilitated if detailed genetic informa-
tion is available. However, requiring genetic testing
for autosomal dominant AD mutations in all or certain
trial participants raises its own set of ethical issues,
requires adjustments to the informed consent pro-
cess, and entails additional procedures that have to
be included in the trial (Fig. 1).
Fig. 1. Decision tree for providing informed consent and for
genetic testing in DBS trials including people with early-onset
Alzheimer’s disease. Solid boxes, lines, and arrows indicate sug-
gestions that must be minimally fulfilled. Dashed boxes, lines, and
arrows indicate optimum suggestions.
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First and foremost, even before having participants
sign an informed consent form, it is important for all
studies to assess their ability to consent using sys-
tematic or established measures of capacity [52, 53].
Participants who do not fully understand the risks of
the invasive neurosurgical procedure or the associated
uncertainty to benefit from the trial, given the limited
data from preliminary studies, should be excluded.
Second, should genetic testing be required, it
should be specified in the informed consent form
that participants will consent to the DBS surgery and
stimulation and all other pre- and post-clinical test-
ing, including genotyping of APP, PSEN1, PSEN2,
and/or APOE. The genotyping that will be per-
formed should be clearly indicated. Both patients
and immediate family members should be given
options to decide whether they would like to have
the results of the genetic tests disclosed or not.
Since approved prevention methods [54] and treat-
ment options for AD do not exist yet, there is no
obligation for deliberate disclosure of genetic test
results to participants and immediate family members
[55]. Nonetheless, pre-disclosure genetic counselling
using established guidelines [56, 57] should be pro-
vided to both patients and immediate family members
to allow them to better understand the implications of
results disclosure [58, 59], particularly on reproduc-
tive [60], insurance [61], and geriatric care planning
and also on potentially being able to access certain
clinical trials for those with autosomal dominant AD
[62]. Should patients and/or immediate family mem-
bers prefer to know results, further support in the form
of post-disclosure genetic counselling sessions could
be provided [57]. It should be emphasized that the risk
of inheriting a mutation from a parent with autosomal
dominant AD is 50%, and immediate family mem-
bers who wish to undergo predictive genetic testing
themselves should be referred to a genetic counsellor,
neurologist, and psychologist/psychiatrist for further
evaluation and support [56, 63]. Consequently, since
payment for further testing and counselling sessions
would raise financial concerns [64] for those conduct-
ing the trial and/or those participating in it, the extent
of genetic counselling and compensation that will be
provided should be clearly indicated in the informed
consent form [51] to better allow family members
to decide on whether they would still prefer to be
informed of the results and understand potential lim-
itations in the support that they would be receiving
in the event of an unfavorable result. Finally, patients
who do not consent to genetic testing should not be
directly excluded from trials and should be offered
alternative options such as family history assessment
[65] for autosomal dominant EOAD risk estimation
and DNA banking [56] for potential genetic testing
after the patient’s death [66], with his or her consent.
Those who do not consent to such alternatives might
be given lower priority to participate in a trial.
Third, since a significant number of studies of
DBS for AD [4, 32] required the consent of fam-
ily members or caregivers, requiring genetic testing
could raise potential issues when the patient but not
the family members would consent to participation
in the trial and consequentially, genetic testing [55].
Although at the start of the trial, participants with
EOAD at a very early disease stage might still have
adequate ability to consent, they might eventually
need a caregiver when the disease rapidly progresses,
and as such, caregivers’ opinions and support on a
patient’s participation in a DBS trial [8] would be of
increasing importance in later trial stages. This high-
lights a potential dilemma when there are conflicting
opinions. The final decision on whether a participant
should participate in a DBS trial and have a genetic
test should then be made only after having a care-
ful and collaborative discussion with the researchers,
clinicians, family members, and the participant. If
there are still conflicting opinions after the delibera-
tion, we recommend that the decision of participants
who have adequate decision-making capacity at the
start of the trial be honored. Should the participant
want to undergo DBS and genetic testing, legal repre-
sentatives and advance research directives [7] should
also be determined and set by the participant prior to
DBS implantation. Given that several states and coun-
tries only allow consent on the subject’s behalf when
the patient has a legal status of incompetence [67],
legal representatives might have to make eventual
decisions on whether to continue DBS stimulation;
however, there might be a point prior to complete
incompetence when the capacity to consent is uncer-
tain and solely obtaining consent from caregivers
would not be the best option from an ethical per-
spective [68]. In such instances, researchers could
also seek assent from participants and exclude those
expressing dissent [7], which may be indicated by
signs or actions of frustration, unhappiness, discom-
fort, or passivity [69].
Disease progression and study design
Only two trials [4, 32] of DBS for AD have a
case-control design, albeit with different durations
in which stimulation was withheld from the control
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group. Withholding DBS for a long time from partici-
pants with EOAD might not be justifiable considering
that DBS is an invasive procedure with potential
unwanted side effects [34, 70, 71], and people with
EOAD might have a more aggressive disease course
and higher mortality than LOAD [72]. It should
also be taken into account that although the Phase
I trial showed that patients who had milder cognitive
symptoms at the time of DBS initiation have seem-
ingly better metabolic and cognitive outcomes [1], the
Phase II trial indicated in its subgroup analysis that
participants <65 actually had worse cognitive scores
after stimulation for one year, whereas the opposite
was observed for those ≥65 [3]. Since results for
each individual participant <65 were not presented,
it is not yet known whether all of them experienced
decline after DBS or if it is only a few with other
characteristics such as lower cognitive profile or more
advanced disease stage. In addition, it would be inter-
esting to know if combining the results for the five
participants <65 in the Phase I fornix DBS trial [1]
with the results for those <65 in the Phase II trial
[3] would still lead to the same observed differential
effect of DBS for this subgroup. Given such uncer-
tainty, it might be possible that some participants <65
could have also benefitted from the stimulation given
that some participants <65 in the Phase I trial [1]
had stabilized or improved cognitive scores following
DBS. For those <65 who might benefit from stimu-
lation and for the rest of participants who were in
the control group, withholding stimulation for a year
could potentially result to a loss of a significant num-
ber of time and treatment opportunities where their
cognition could still be stabilized. Although patients
will continue receiving medications for memory dur-
ing the period without stimulation, limiting them
from attaining any eventual potential benefit from
the surgery and even potentially causing them harm
should any untoward incident result from surgery or
stimulation would be unfair. On the other hand, for
those <65 wherein stimulation could be disadvanta-
geous, having a shorter stimulation time instead of
one year could have potentially allowed initial detec-
tion of the stimulation’s potential adverse effect, and
appropriate actions could have been taken to prevent
further harm in these patients.
The initial results of the Phase II trial also bring
into question whether the study design has to be
modified given that those <65 might be disadvan-
taged. It is important for Lozano et al. [3] to look at
individual patients who deteriorated the most in the
<65 stimulation group and see whether stimulation
might need to be stopped for them instead of allow-
ing them to continue to the one year open stimulation
phase. In addition, those who are <65 who were orig-
inally assigned to the control group and have similar
cognitive profiles as those who were most severely
disadvantaged by DBS might not need to participate
in the trial’s next phase and not receive any stimu-
lation given that these participants might actually be
harmed by it. Although these adjustments to the study
design could have some effect on the study’s power
if ever implemented, it is more important to protect
participants’ welfare, especially if there is convincing
evidence that their further participation could lead to
avoidable harms.
In terms of patient monitoring, studies usually
monitored performance in various cognitive and
neuropsychiatric tasks a month, three months, six
months, and a year after surgery. However, when
participants with a potentially more rapid disease pro-
gression are included [23], more frequent monitoring
(bimonthly or monthly) should be implemented.
Given that those <65 who received stimulation for
one year in the Phase II trial had worse outcomes
than those who did not [3], much more frequent
monitoring would have allowed the initial detection
of this potential worsening and would have allowed
more data to be obtained to determine the rate of
disease progression and compare it with that prior
to stimulation or with historical controls. Moreover,
given that some people with AD-EOAD experience
atypical symptoms [19] such as behavioral impair-
ment, apraxia, and aphasia, stringent examination
and careful neuropsychiatric monitoring before and
post-implantation should be made to ensure that
any neuropsychiatric or motor attributes would not
be affected in a way that is detrimental to the
patient.
Potential trial outcomes
All the trials that have been completed [1, 2, 4]
and the Phase II trial [32] that is ongoing assessed
the efficacy of DBS using a cognitive test (MMSE,
ADAS-Cog, CDR, FCSRT); however, several studies
have also employed measurements of metabolism via
PET [1, 2, 4, 29, 32], brain activity through EEG [4],
and changes in hippocampal volume through MRI
[1, 32]. Some studies also assessed the participant’s
quality of life [1, 4, 32]. For the Phase I studies [3, 5],
results on the quality of life have been inconsistent
with an increase in some participants and a decrease
in others. For the Phase II trial, Holroyd et al. [32]
C
rre
cte
d P
r o
f
J.N.M. Vian˜a et al. / Ethics of DBS Trials in Patients with EOAD 9
mentioned that they will be including the Quality of
Life – Alzheimer Disease measure [73]; however,
Lozano et al. [3] did not mention the result of this
test in the report they have published [9]. All studies
have also reported improved or preserved neurologic
activity in certain brain areas; however, the translata-
bility of these improvements to the trial participants’
quality of life and daily functioning has yet to be
adequately proven.
Although in general, the final pathophysiology in
EOAD and LOAD may be greatly similar, the ini-
tial disease progression and onset of EOAD and
LOAD might have some differences that could lead
to potentially variable outcomes during early disease
stages. For instance, EOAD patients have more pro-
nounced atrophy in neocortical areas as opposed to
LOAD patients wherein atrophy is more severe in the
hippocampus [74]. Moreover, EOFAD patients also
present with apraxia, aphasia, or dysexecutive syn-
drome [19]. As such, additional modes of assessment
should be performed in studies involving patients
with EOAD to determine how DBS affects these
cognitive domains and motor symptoms. It might
also be possible that EOAD patients might have a
different initial clinical outcome given that degener-
ation usually is not as prominent in the hippocampus.
Depending on the target region for DBS, the extent
of changes or duration of stabilization in cogni-
tive scores could differ between EOAD and LOAD
patients. Although the results of the Phase II trial
might indicate that fornix DBS could potentially
be disadvantageous for those <65 [3], such might
not necessarily be the case for NBM stimulation.
Given these, it is important to properly convey these
potential sources of differential DBS response to
EOAD patients, especially those with family his-
tory and mutation in APP, PSEN1, or PSEN2, so
that they will be more informed when they consent
to the procedure and also to increase the likelihood
that they will monitor the effects of stimulation on
these atypical symptoms once the trial has been
initiated.
Interpretation and communication of study
results
Results of preliminary studies are used to plan
the next stages of clinical trials [75]; however, they
should not be used to justify efficacy and safety
[75, 76] in a clinical setting. It is important that
trials should convey this in their discussion and con-
clusion to prevent creating false hype. In addition,
they should also highlight limitations in their
methodology that could have affected study results.
For example, Kuhn et al. [4] mentioned that it proved
impossible for them to precisely insert the elec-
trode in their preselected target due to degenerative
or pathological vascular alterations. Although they
mentioned this as a limitation of their study, they
should have reflected more on whether this limita-
tion would then make precise targeting of a desired
region in the NBM totally not feasible instead of
just concluding that DBS of the NBM is “techni-
cally feasible”. In addition, they also mentioned that
NBM DBS “apparently lacks significant stimulation-
induced untoward effects”; however, they mentioned
that one patient required lorazepam during the stim-
ulation phase without fully describing why and at
which exact points during the open stimulation phase
was the drug prescribed. Finally, it is important to
emphasize that the conclusion that DBS is “well
tolerated” and that “four out of six patients were
responders” should only be considered in the con-
text of deciding whether to do a subsequent clinical
trial in a proper and well-regulated research setting
and not allowing for NBM DBS to be performed on
anyone with AD in a clinical setting given that the
study’s limited sample size is inadequate to capture
a wide range of potential adverse events and derive
any statistically valid conclusion on the efficacy
of DBS.
Another important aspect in reports of trials is
for authors to completely report the results of all
statistical tests that they perform. In the results of
the Phase II trial [3], the observed difference in
results between those who received stimulation and
those who did not is much more dramatic for those
<65, whereas only slight improvements in cogni-
tive function were observed for those who are ≥65.
Although the authors mentioned the result of the sta-
tistical tests for the <65 group, they did not provide
p values for the ≥65 group for readers to deter-
mine the significance of the observed decline between
those who received and those who did not receive
stimulation.
Finally, it is important to consider that the 65
years cut-off point has no biological significance and
is mainly based on employment and retirement age
[15]. As such, it is crucial that further analysis for
the Phase II trial [3] should be performed based on
other factors such as disease stage, cognitive scores
at the start of the trial, and/or extent of AD pathol-
ogy based on biomarkers such as brain volume and
levels of tau and/or A in cerebrospinal fluid [9,
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46]. In addition, relating genetic data to treatment
outcomes could potentially allow for better explana-
tion of results obtained for those <65. It is possible
that those who were made worse off by DBS have
genetic mutations that result to a more aggressive
disease course [16], and these individuals are also
at a later disease stage at the trial onset. Report-
ing effects for participants having known mutations
might require presentation of individual de-identified
data to facilitate comparison of the rates of progres-
sion for individuals possessing mutations in known
genes and accurately determine if DBS might have
affected the rate of disease progression for these par-
ticipants. Although introducing other variables in the
analysis would add another level of complexity, they
could facilitate improved understanding of the factors
that affect DBS response, allowing better selection of
suitable participants in future trials. Caution should
be exercised in drawing conclusions though given that
analysis based on subgroups usually lacks adequate
power and may yield false-negative results, unless the
initial trial power calculation significantly accounted
for eventual subgroup analysis [77].
CONCLUDING REMARKS AND FUTURE
CONSIDERATIONS
Studies that conducted DBS in patients with AD
have not screened patients less than 65 years old for a
family history of EOAD; mutations in APP, PSEN1,
or PSEN2; or have APOE alleles that could affect
age of disease onset and potentially, rate of progres-
sion [78]. As such, participants who have a familial
or genetic AD that have a more aggressive disease
course might have been disadvantaged by trials in
terms of the employed study design and frequency of
monitoring.
Although we believe that larger studies on DBS
for EOAD should only be conducted after an exten-
sive positive appraisal of the long-term results of
the ongoing Phase II trial taking into account pre-
vious trials and relevant animal studies, we would
like to propose certain precautionary recommenda-
tions for potential trials in the future that would
include participants <65 (Table 2). First, in terms
of patient selection, EOAD patients who have psy-
chiatric disorders, suicidal ideations, and who are
Table 2
Recommendations for DBS clinical trials, especially those involving participants with EOAD, based on gaps in current and previous trials
and case studies
Clinical Trial Aspect Recommendations
Participant Selection • Exclude participants who have a major psychiatric disorder, suicide history, and suicidal ideations.
• Exclude participants beyond the mild cognitive impairment/ very mild AD stage (CDR score >0.5, MMSE
score <23, and ADAS-Cog 11 score >18).
• Use potential biomarker information to better estimate disease stage.
Genetic Testing • Test for mutations in APP, PS1, and PS2, and if possible, determine APOE alleles possessed (for research
purposes).
• Provide pre-test and post-disclosure genetic counselling to participants and their immediate family.
Informed Consent • Assess ability to consent using established measures of capacity.
• Request consent both for DBS and genetic testing.
• Offer alternative options such as DNA banking for those who do not wish to undergo genetic testing.
• Clearly indicate what counselling and predictive genetic testing will be performed and which services are
covered by the trial organizers.
• Collaborative decision making should be made in case of conflicting opinions; however, a participant’s
decision should be honored if he or she has adequate capacity to consent.
• Assign legal representatives and advance directives for participants.
• Incorporate patient assent and dissent in decision-making in later trial stages.
Trial Design • Initially assign a shorter stimulation period (<1 year).
• Stimulation might have to be discontinued in the event of evident cognitive decline from DBS.
• Monitor participants more frequently (monthly or bimonthly) and include assessments for atypical symptoms
in people with EOAD and for neuropsychiatric changes.
Outcome Measures • Include quality of life measurements in trials and report their results in publications.
• Include additional modes of assessment for atypical symptoms in people with EOAD.
• Acknowledge potentially variable outcomes between EOAD and LOAD participants and possibly different
effects of fornix and NBM DBS on different patient subgroups.
Reporting of Results • Realistically convey whether certain methodological limitations affect feasibility of DBS for particular
regions.
• Provide more specific details of adverse events and how they were addressed.
• Completely report results of all statistical tests.
• Analyze other variables that could result to different responses to DBS such as disease stage and genetic
status.
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already at the dementia phase should be excluded in
studies until results suggest that DBS might also be
effective in later AD stages. Second, genetic screen-
ing of patients <65 years old should be included
in trials; however, disclosure of results has to be
discussed with patients and relatives. Third, appro-
priate adjustments on the length of exposure to
trial arms, assessments performed, and frequency of
monitoring should be made to accommodate dif-
ferences in EOAD and LOAD should people <65
be included. Fourth, study results should be real-
istically conveyed and should be reported equally
regardless of the direction of the effect. Researchers
and the media should be careful not to hype up
results of preliminary studies to ensure that EOAD
patients volunteering to enroll in an experimen-
tal trial are fully informed and not just misled by
overly positive depictions of DBS for AD [79].
Finally and most importantly, collaboration between
basic researchers, neurologists, psychiatrists, neuro-
surgeons, genetic counsellors, ethicists, and other
aged care personnel should be established to set
a proper framework ensuring that patients with
EOAD are appropriately prepared and informed,
well-protected, unharmed, and are not deprived of
potential therapeutic benefits in future clinical trials
of DBS for AD.
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